1.1Oral enzyme inhibition
The drug slows the breakdown of cyclic guanosine monophosphate in cavernous smooth muscle. During sexual stimulation, this action supports smooth muscle relaxation and increases blood flow into erectile tissue.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The drug slows the breakdown of cyclic guanosine monophosphate in cavernous smooth muscle. During sexual stimulation, this action supports smooth muscle relaxation and increases blood flow into erectile tissue.
A single-use applicator places a pellet containing prostaglandin E1 in the urethra. The drug dissolves and passes into nearby erectile tissue, where it relaxes smooth muscle and increases arterial inflow.
A hand pump lowers air pressure inside a sealed cylinder placed over the penis. The pressure difference draws blood into the penis, and an elastic ring at the base reduces venous outflow after the cylinder is removed.
A manual pump transfers fluid from a reservoir into paired cylinders placed in the corpora cavernosa. Cylinder expansion provides rigidity, and a release valve allows fluid to return to the reservoir.
Radiofrequency current passes between a small treatment electrode and a broad return pad placed away from the treatment site. Current density is highest near the treatment electrode, where resistive heating produces the thermal exposure used to remodel collagen.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A biomedical equipment workshop mounts a layered silicone and hydrogel tissue model on a rigid base. The service sequence logs a simulated hormone administration, applies acoustic pulses and bipolar radiofrequency to the model, and injects dyed saline through a replaceable membrane. An embedded pressure sensor and thermocouple record the acoustic and thermal responses, and a transparent sidewall exposes the injection pattern for inspection.
A motorized syringe driver replaces manual movement of the plunger during the tissue composition injection. A lead screw advances the plunger of a sterile syringe connected directly to the needle, and a linear encoder measures plunger travel. The controller converts the entered volume to travel using the syringe bore area, stops at the target position, and halts motion if the measured plunger force exceeds the configured limit.
A removable applicator guide divides the selected acoustic treatment surface into four indexed sectors. The operator seats the applicator at each position and assigns 25 percent of the entered session pulse count to that sector, with any rounding remainder assigned to the final sector. The controller displays the current sector and its remaining pulse count, and it resumes an interrupted sector from the saved count.
A clinical charting system groups the four treatment modalities under a single treatment episode identifier. The hormone and injection entries store the administered quantity, time, and material lot, while the acoustic and radiofrequency consoles supply their delivered pulse counts and temperature traces through a device gateway. The chart displays the four records in chronological order and links each imported measurement to its source console.
A B-mode ultrasound scanner stores images of the selected treatment region with its probe position referenced to a gridded skin marker. The operator marks a target and its measured depth on the image, and the workstation stores those coordinates with the acoustic and radiofrequency applicator positions for the session. During injection, a probe-mounted needle guide aligns the needle with the imaging plane so the operator can observe the tip relative to the marked target.
A bipolar applicator places a surface temperature sensor between its electrodes and measures impedance across the electrode pair. A controller samples both signals during delivery and suspends output when either measurement leaves its configured operating interval or becomes unavailable. The controller logs the readings at the interruption and requires operator confirmation before resuming output.
A metered pump dispenses testosterone in a hydroalcoholic gel for application to intact skin. Testosterone passes through the skin into circulation, and serum testosterone measurements guide dose adjustment in patients with confirmed deficiency.
A pulsed electromagnetic coil drives a metal membrane to create a pressure pulse. An acoustic lens focuses the pulse into a defined treatment volume, and a gel layer couples the applicator to the skin.
Two adjacent electrodes on a handheld applicator pass radiofrequency current through the tissue between them. A contact temperature sensor feeds back to the generator, which adjusts power to control surface temperature during heating.
Centrifugation separates and concentrates platelets from a sample of the patient's blood. A syringe delivers the resulting platelet-rich plasma into cavernous tissue, where activated platelets release signaling proteins.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The attending physician will consider using a variety of therapies to treat sexual dysfunction including, platelet-rich plasma (PRP) procedure, Wharton's jelly, exosome therapy, peptides, hormone therapy, intra-corporeal injections, hyperbaric oxygen therapy, pulsed electromagnetic field therapy, or use of PDE5 medications, penal implants, and/or psychological therapy.A · US 11,564,861 B1 · ¶ 34
The treatment includes administering hormone regenerative therapy (HRT) to the patient, administering acoustic shockwave therapy to the genitalia to generate new vascularity in the genitalia, administering a laser treatment to the genitalia and administering a shot of a tissue regeneration composition to the genitalia to regenerate tissue.B · US 11,806,301 B1 · ¶ 12
The medical procedure includes treating strategic, gender-specific anatomical regions of male and female genitalia with radial and focused extracorporeal shockwave therapy (ESWT) at prescribed bar values, frequencies, and shockwave amounts, to promote production of new vasculature, blood circulation and cell growth to treat sexual and erectile dysfunction and improve sexual health function.A · US 11,564,861 B1 · ¶ 8
The treatment includes administering hormone regenerative therapy (HRT) to the patient, administering acoustic shockwave therapy to the genitalia to generate new vascularity in the genitalia, administering a laser treatment to the genitalia and administering a shot of a tissue regeneration composition to the genitalia to regenerate tissue.B · US 11,806,301 B1 · ¶ 12
A method of treating sexual disfunction of genitalia of a human patient, comprising: administering hormone regenerative therapy (HRT) to the patient; administering accoustic shockwave therapy to the genitalia to generate new vascularity in the genitalia; administering a laser treatment to the genitalia using an neodymium-doped yttrium aluminum garnet (Nd:YAG) laser pulsed with a 8 second pulse duration, 9 mm spot size, 180 J/cm2, for 4 minutes on each side of the genitalia, tB · US 11,806,301 B1 · claim 1
The treatment includes administering hormone regenerative therapy (HRT) to the patient, administering acoustic shockwave therapy to the genitalia to generate new vascularity in the genitalia, administering a laser treatment to the genitalia and administering a shot of a tissue regeneration composition to the genitalia to regenerate tissue.B · US 11,806,301 B1 · ¶ 12
An empty cell means only that no passage was reproduced there.
The present invention relates to medical methods or procedures, and more particularly, to a medical procedure using dual, i.e., radial and focused extracorporeal shockwave therapy (ESWT) for treating strategic, gender-specific anatomical regions of both males and females suffering from erectile and sexual dysfunction to improve sexual health function.A · US 11,564,861 B1 · ¶ 2
Advancements in medical therapies and prescribed medicines have provided limited benefits in treating sexual dysfunction including erectile dysfunction.A · US 11,564,861 B1 · ¶ 5
The present subject matter relates to treating and reversing sexual disfunction in male and female humans.B · US 11,806,301 B1 · ¶ 1
While pharmaceuticals, such as PDE5 inhibitors, may lend a temporary effect in giving an erection, they do not address the root causes of erectile dysfunction.B · US 11,806,301 B1 · ¶ 2
patent.fyi, US 2026/0355050 A1, claim 1, first published 2026-11-19T07:16:45-05:00, https://patent.fyi/US20260355050/, SHA-256 70cd3656d57dc6d8a93e8f3aaa61bfb5ce7c56a703adfa428fcd836edf920307